American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 59-69 , July 2009

Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Received 25 February 2009 ,Accepted 10 April 2009.

References 

  1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet. 2006;368:29–36
  3. Stengel B, Billon S, Van Dijk PC, et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant. 2003;18:1824–1833
  4. Foley RN, Collins AJ. End-stage renal disease in the United States: An update from the United States Renal Data System. J Am Soc Nephrol. 2007;18:2644–2648
  5. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–1419
  6. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591
  8. Locatelli F, Pisoni RL, Combe C, et al. Anemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121–132
  9. Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 2003;41:520;author reply, 521
  10. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int. 2003;63:1499–1507
  11. Pfeffer MA, Solomon SD, Singh AK, Ivanovich P, McMurray JJ. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005;6(suppl 3):S35–S41
  12. Mix TC, Brenner RM, Cooper ME, et al. Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–413
  13. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  14. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  15. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: We were wrong, time to move on. Lancet. 2007;369:346–350
  16. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease [letter]. N Engl J Med. 2007;356:959–961
  17. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  18. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation. 2007;115:1544–1550
  19. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  20. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  21. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803–1810
  22. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
  23. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled?. Ann Intern Med. 1996;125:605–613
  24. Pfeffer MA. Critical missing data in erythropoiesis-stimulating agents in CKD: First beat placebo. Am J Kidney Dis. 2008;51:366–369
  25. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease (Results of a phase III multicenter clinical trial). Ann Intern Med. 1989;111:992–1000
  26. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
  27. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  28. Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study—Follow-up. N Engl J Med. 2008;358:433–434
  29. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548–554
  30. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207
  31. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381–388
  32. Levin A. Understanding recent haemoglobin trials in CKD: Methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007;22:309–312
  33. Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions (A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)). Kidney Int. 2008;74:1237–1240
  34. FDA black box warning for Aranesp. http://www.fda.gov/cder/foi/label/2008/103951s5195PI.pdf.Accessed May 15, 2009
  35. Gandhi GY, Murad MH, Fujiyoshi A, et al. Patient-important outcomes in registered diabetes trials. JAMA. 2008;299:2543–2549

 A list of author affiliations appears at the end of this article.

 Originally published online as doi:10.1053/j.ajkd.2009.04.008 on June 8, 2009.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Peter McCullough, MD, MPH, William Beaumont Hospital) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

 A list of the TREAT Investigators is provided as online supplementary material for this article.

 Trial Registration: www.clinicaltrials.gov; study number: NCT00093015.

PII: S0272-6386(09)00640-4

doi: 10.1053/j.ajkd.2009.04.008

American Journal of Kidney Diseases
Volume 54, Issue 1 , Pages 59-69 , July 2009

Article Tools